Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa
September 30 2019 - 9:04AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam
Muzikant, Ph.D., Senior Vice President, Business Development, will
present at the annual Cell & Gene Meeting on the Mesa in
Carlsbad, California. Dr. Muzikant will provide an overview and
update on FX201, Flexion’s preclinical gene therapy product
candidate for the treatment of osteoarthritis (OA), on Wednesday,
October 2, 2019 at 5:30 p.m. ET (2:30 p.m. PT).
Organized by the Alliance for Regenerative Medicine, the Cell
& Gene Meeting on the Mesa is a three-day conference featuring
more than 80 presentations by leading public and private companies.
The meeting highlights technical and clinical achievements in the
areas of cell therapy, gene therapy, gene editing, tissue
engineering and broader regenerative medicine technologies.
A live video webcast of Dr. Muzikant’s presentation will be
available at: http://www.meetingonthemesa.com/webcast and will also
be published on the conference website shortly after the event.
About FX201 FX201 is a preclinical, locally
administered gene therapy product candidate designed to stimulate
the production of an anti-inflammatory protein, interleukin-1
receptor antagonist (IL-1Ra), whenever inflammation is present
within the joint. Inflammation is a known cause of pain, and
chronic inflammation is thought to play a major role in the
progression of OA. By persistently suppressing inflammation,
Flexion believes FX201 holds the potential to both reduce OA pain
and modify the disease. Both GMP manufacturing of clinical trial
material and IND-enabling nonclinical studies have been completed
for FX201, and Flexion expects to initiate first-in-human clinical
studies by the end of 2019.
About Flexion Therapeutics Flexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. For the past three years,
Flexion has been named one of the Best Places to Work by the Boston
Business Journal, and Flexion was also recognized as a Top Place to
Work in Massachusetts by The Boston Globe in 2017 and 2018.
Forward-Looking Statements Statements in this
press release regarding matters that are not historical facts,
including, but not limited to, statements relating to the future of
Flexion; our plans to develop and commercialize FX201, including
the expected timing of clinical and regulatory events; and the
potential therapeutic and other benefits of FX201, are
forward-looking statements. These forward-looking statements are
based on management's expectations and assumptions as of the date
of this press release and are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation, risks
associated with developing FX201; the fact that the results of
prior preclinical studies may not predict results of subsequent
preclinical or clinical studies; the risk that we may incur
unexpected expenses or cash requirements; our reliance on third
parties to manufacture FX201; the risk that we may not be able to
maintain and enforce our intellectual property, including licensed
intellectual property related to FX201; the risk the license
agreement with Baylor could be terminated early if we do not comply
with our obligations; competition from alternative therapies;
regulatory developments and safety issues, including difficulties
in obtaining and maintaining regulatory approvals to conduct
clinical trials and market FX201; risks related to key employees,
markets, economic conditions, health care reform, prices and
reimbursement rates; and other risks and uncertainties described in
our filings with the Securities and Exchange
Commission (SEC), including under the heading "Risk Factors"
in our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2019. The forward-looking statements in this
press release speak only as of the date of this press release, and
we undertake no obligation to update or revise any of the
statements. We caution investors not to place considerable reliance
on the forward-looking statements contained in this press
release.
Contact:
Scott YoungVice President, Corporate Communications &
Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Julie DownsSenior Manager, Corporate Communications &
Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Sep 2023 to Sep 2024